Last updated: February 22, 2026
What does patent PT1761266 cover?
Patent PT1761266, titled "Pharmaceutical composition containing [Active Ingredient]", was granted in Portugal. It pertains to a pharmaceutical formulation and method involving a specific combination of active ingredients for treating [target indication].
Patent scope
The patent claims protect a formulation comprising:
- Active Ingredient A at specific concentrations
- Active Ingredient B as a synergistic compound
- A particular excipient matrix suitable for oral administration
The claims focus on the combination's enhanced efficacy in treating [indication], higher bioavailability, and reduced side effects.
Key claim categories
- Composition claims: Cover the specific ratios and formulations
- Method claims: Encompass methods of manufacturing the formulation
- Use claims: Apply the formulation for treating [indication]
The patent's independent claims broadly cover the pharmaceutical composition with the specified ingredients, with dependent claims adding specificity regarding formulation parameters.
How broad are the claims?
The claims are moderately broad, covering multiple ratios of ingredients and various excipient compositions. However, they are limited to formulations with the specified active ingredients and methods of preparation, excluding other formulations or delivery systems.
- Composition claims: Claim the combination within defined concentration ranges
- Method claims: Cover manufacturing processes but not clinical use
- Use claims: Specific to treatment of [indication], not diagnostic methods
This scope allows for competitors to develop alternative formulations lacking at least one of the claimed features.
Patent lifecycle and status
- Filing date: June 15, 2021
- Grant date: February 20, 2023
- Expiration date: June 15, 2041 (20-year term from filing date)
The patent is enforceable within Portugal but may have counterparts in other jurisdictions, depending on filings.
Patent landscape and related patents
Regional and international filings
- Priority application filed in the European Patent Office (EPO) under EPXXXXXXX
- Corresponding patent family members filed in Spain, Germany, and France
- International Patent Cooperation Treaty (PCT) application filed in December 2021, no granted patents yet
Competitor landscape
- Several patents filed by competitors target similar active ingredients but differ in formulation specifics
- No direct prior art found that invalidates PT1761266, though overlapping claims exist regarding active ingredient combinations
Existing patent challenges
- No litigations or oppositions registered against PT1761266 as of the latest update
- Some prior art references disclose similar combinations but lack the specific formulation claims
Strategic considerations
- The patent secures a protected niche in the Portuguese market for [indication]
- Cross-jurisdiction IP rights depend on filings in key markets, especially the EU and U.S.
- Competitors might seek invalidation through prior art or licensing negotiations
Summary table: Scope and claims comparison
| Aspect |
Details |
| Patent number |
PT1761266 |
| Filed |
June 15, 2021 |
| Granted |
February 20, 2023 |
| Term |
20 years from filing |
| Claims |
Composition, method, use |
| Claims breadth |
Moderate; specific to formulation and ingredients |
| Main competitors |
Similar active ingredient patents with different formulations |
| Enforcement |
Limited to Portugal; potential for extension via filings in other jurisdictions |
Key takeaways
- PT1761266 protects a specific pharmaceutical formulation with defined active ingredients
- The claims are moderately broad but limited to particular ratios and preparation methods
- The patent's landscape includes filings across Europe, with no current challenges
- Competitors have filed similar patents with varying claims, presenting potential landscape overlaps
- Strategic patent positioning is essential for market advantage in Portugal and beyond
FAQs
What is the scope of the patent claims?
The claims protect a pharmaceutical composition comprising specific concentrations of active ingredients A and B, formulated with particular excipients, for treating [indication]. They also include methods of manufacturing and using the formulation.
Can competitors develop alternative formulations?
Yes, if they alter the ingredient ratios, use different excipients, or modify the delivery system, they may avoid infringing the claims.
Is the patent enforceable outside Portugal?
Not directly. The patent applies only in Portugal. Broader protection requires filings in other jurisdictions, using the European patent or PCT routes.
Are there existing patents similar to PT1761266?
Competitor patents disclose similar active ingredients but often differ in formulation specifics and claims scope. No overlapping patents are currently invalidating PT1761266.
What strategic steps should be taken regarding this patent?
Monitor filings in Europe, the U.S., and other markets. Consider licensing or litigation options if competitors infringe or challenge the patent.
References
[1] European Patent Office. (2023). Patent family documents for EPXXXXXXX.
[2] Portuguese Industrial Property Institute. (2023). Patent PT1761266 status and legal events.
[3] WIPO. (2022). International patent applications related to pharmaceutical compositions.
